{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:01:26Z","timestamp":1762077686551,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008583","name":"Stiftelsen Erik and Lily Philipsons Minnesfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008583","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ahj.2018.02.011","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T02:32:30Z","timestamp":1518748350000},"page":"141-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Caffeine and incidence of dyspnea in patients treated with ticagrelor"],"prefix":"10.1016","volume":"200","author":[{"given":"Daniel","family":"Lindholm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar \u00d6","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Heller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Henriksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Lauermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrik","family":"\u00d6hagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Varenhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ahj.2018.02.011_bb0005","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ahj.2018.02.011_bb0010","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ahj.2018.02.011_bb0015","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1093\/eurheartj\/ehr231","article-title":"Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes","volume":"32","author":"Storey","year":"2011","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.ahj.2018.02.011_bb0020","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jacc.2012.11.032","article-title":"Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans","volume":"61","author":"Wittfeldt","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ahj.2018.02.011_bb0025","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2013.09.067","article-title":"Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome","volume":"63","author":"Bonello","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ahj.2018.02.011_bb0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1074248413511693","article-title":"Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1","volume":"19","author":"Armstrong","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.ahj.2018.02.011_bb0035","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ahj.2015.06.014","article-title":"Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr","volume":"170","author":"Lindholm","year":"2015","journal-title":"Am Heart J"},{"issue":"17","key":"10.1016\/j.ahj.2018.02.011_bb0040","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1001\/jama.298.17.2009","article-title":"Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials","volume":"298","author":"McMurray","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2018.02.011_bb0045","first-page":"e0137560","article-title":"Ticagrelor Does Not Inhibit Adenosine Transport at Relevant Concentrations: A Randomized Cross-Over Study in Healthy Subjects In Vivo","volume":"10(10)","author":"van den Berg","year":"2015"},{"issue":"3","key":"10.1016\/j.ahj.2018.02.011_bb0050","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1161\/CIRCINTERVENTIONS.113.000293","article-title":"Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study","volume":"6","author":"Alexopoulos","year":"2013","journal-title":"Circ Cardiovasc Interv"},{"issue":"7","key":"10.1016\/j.ahj.2018.02.011_bb0055","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/09537104.2016.1265919","article-title":"Dyspnea in patients treated with P2Y12 receptor antagonists: insights from the GReek AntiPlatElet (GRAPE) registry","volume":"28","author":"Alexopoulos","year":"2017","journal-title":"Platelets"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318300541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318300541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:56:32Z","timestamp":1762077392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870318300541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":11,"alternative-id":["S0002870318300541"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2018.02.011","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Caffeine and incidence of dyspnea in patients treated with ticagrelor","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2018.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}